Physician profile
Timothy Jones
NPI 1487726279
$2,965.44
in general payments reported to CMS, 2019-2025
29 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $441 · 2023: $545 · 2024: $764 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,351.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,012.29 | 2021-2025 | Relistor, Xifaxan |
| Collegium Pharmaceutical, INC. | $279.16 | 2023-2025 | Xtampza, Belbuca |
| Abbvie INC. | $215.52 | 2022-2025 | |
| Virtus Pharmaceuticals LLC | $168.39 | 2022-2025 | Levorphanol Tartrate |
| Valinor Pharma, LLC | $161.32 | 2023-2024 | Movantik |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $159.79 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $149.89 | 2025 | |
| Scilex Pharmaceuticals INC. | $146.53 | 2021-2023 | Ztlido |
| Medtronic, INC. | $68.87 | 2023-2024 | Intellis Adaptivestim |
| Biodelivery Sciences International, INC. | $57.32 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $52.57 | 2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $51.89 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $49.90 | 2023-2025 | |
| Arbor Pharmaceuticals, INC. | $40.56 | 2021 | |
| Novo Nordisk INC | $39.15 | 2025 | Wegovy, Rybelsus, Ozempic |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $38.79 | 2025 | Rexulti |
| Lilly USA, LLC | $33.50 | 2025 | Zepbound, Mounjaro, Jardiance |
| Curonix LLC | $33.34 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Kowa Pharmaceuticals America, INC. | $27.75 | 2023 | Seglentis |
| Protega Pharmaceutials INC | $21.96 | 2024 | Roxybond |
| Xeris Pharmaceuticals, INC. | $20.72 | 2025 | Gvoke Hypopen |
| Cranial Technologies, INC | $20.31 | 2025 | Doc Band |
| Redhill Biopharma INC. | $18.28 | 2021 | |
| Boston Scientific Corporation | $17.98 | 2024 | Intracept |
| Vanda Pharmaceuticals INC. | $17.88 | 2025 | Fanapt, Hetlioz |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.14 | 2022 | |
| Corcept Therapeutics | $15.47 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.12 | 2025 | Jardiance |
| Horizon Therapeutics Plc | $15.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.